Practice implications and recommendations for managing codeine misuse and dependence by Bergin, M et al.
 Bergin, M, Norman, I, Foley, M, Harris, R, Rapca, A, Rich, E and van Hout, MC
 Practice implications and recommendations for managing codeine misuse 
and dependence
http://researchonline.ljmu.ac.uk/9687/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Bergin, M, Norman, I, Foley, M, Harris, R, Rapca, A, Rich, E and van Hout, 
MC (2015) Practice implications and recommendations for managing 
codeine misuse and dependence. Acta Pharmaceutica, 65 (4). pp. 351-364. 
ISSN 1330-0075 
LJMU Research Online
351
Acta Pharm. 65 (2015) 351–364 Mini review
DOI: 10.1515/acph-2015-0040
Practice implications and recommendations for managing 
codeine misuse and dependence
Codeine, a weak opiate, requires increased pharmacovigi-
lance relating to availability, heterogeneous nature of mis-
use, dependence and associated harm. A scoping review of 
literature on codeine was conducted using Arksey & 
O’Malley’s framework (1). Databases searched included 
PubMed, EBSCO Host, Science Direct, EMBASE, PsycINFO, 
Cochrane library and Medline from 1994 to 2014. Follow-up 
search strategies involved hand searching and searching of 
pharmaceutical, health, medical and drug related websites. 
Initial zscreening identiied 3,105 articles with 475 meeting 
the inclusion criteria. Eight broad categories organised the 
literature, data charting and qualitative synthesis. This pa-
per presents implications for practice and makes recom-
mendations to address these issues. Themes identiied re-
late to raising public and practitioner awareness, risk 
management, dispensing practices and monitoring and 
surveillance of codeine. Evidence to inform law enforce-
ment, drug surveillance, public health initiatives, harm 
reduction approaches, pharmacy, clinical and treatment 
practices is warranted.
Keywords: codeine, over the counter, misuse, dependence, 
policy
Codeine or 3-methylmorphine is a weak opioid, widely used for its analgesic, antitus-
sive and anti-diarrheal properties, and most commonly in the management of mild to 
moderate pain and is available in non-prescription products in low doses (2, 3). However, 
codeine does not compare favourably to commonly used non opioid analgesic alternatives 
such as NSAIDs or paracetamol and appears more clinically useful when combined with 
paracetamol (2). The global demand for codeine has, however, risen by approximately 27 
% over the last two decades with recent igures estimating that codeine consumption 
reached an all-time high at 269 tonnes in 2011 (compared to 164 tonnes in 1992) (4). More-
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over, policy across the European Union (EU) member states varies in relation to public 
access to over the counter (OTC) sales of codeine containing medicines. Currently, 15 of the 
28 EU member states do not permit OTC codeine sales (5).
Codeine is a listed narcotic drug under international control and is regulated to vary-
ing degrees by the regulatory authority of medicines in individual countries (5). Pure co-
deine is listed under Schedule II of the 1961 Convention on Narcotic Drugs. However, most 
codeine preparations classiied under Schedule III are pharmacy controlled with no re-
quirement to keep controlled registers (5). Deregulation of OTC codeine containing medi-
cines has led to increased choice, self-medication and pharmacist empowerment around 
codeine dispensing (6, 7). Both therapeutic and non-therapeutic misuse of these products 
centre on use outside acceptable medical guidelines, instructions on the dispensing labels 
or the intended purposes (7). 
Codeine use and misuse
EU prevalence data on codeine use, misuse and dependence is largely conined to 
French and Norwegian studies with prevalence rates in other European countries unclear 
(5, 7). A prevalence study of the non-medical use of prescription opioids in the USA (2008–
2009) found that a substantial number of individuals reported using combination products 
containing codeine with paracetamol (8). The misuse of combination products containing 
non-opioid analgesics (ibuprofen, paracetamol, aspirin) and codeine is increasing in coun-
tries where OTC products are available (5), with increased levels of tampering with OTC 
cold and lu products to extract codeine for intoxication purposes reported (9). Further-
more, OTC sales of codeine containing medicines is diicult to determine due to trade 
exemptions and the fact that disclosures of such information might prejudice commercial 
interests (7). 
The displacement of public OTC purchasing of analgesic drugs without medical con-
sultation has led to an increase in self-medication with potentially habit forming medica-
tions (10). Conlicting views exist with regard to codeine’s potential for addiction, particu-
larly when considering combination products and the potential adverse efects of other 
active ingredients such as ibuprofen, paracetamol and cafeine on excessive or long term 
use (11–13). Although efects are milder than those of heroin, tolerance occurs with regular 
use over a short period of time (14, 15). Withdrawals include classic opiate dependence 
symptoms, which are generally less severe than with morphine (16).
Eforts to understand and quantify levels of public misuse of OTC codeine containing 
medicines and the impact of associated adverse health consequences remain problematic 
due to its heterogeneous nature and the broad nature of misuse. Issues relating to codeine 
misuse include widespread retail availability in OTC products and inability of pharmacies 
and regulatory agencies to monitor misuse (5, 7). Codeine’s opioid analgesic efect and 
development of tolerance within a short time frame contribute to its potential habit form-
ing use, misuse pathways and addiction (11). Consequences of codeine use and misuse can 
be grouped under four main categories: (i) impairment, (ii) injury such as greater risk of 
fractures, particularly in older people (iii) adverse health efects relating to combination 
analgesics such as perforated gastric ulcers, gastrointestinal bleeding, hepatotoxicity, hy-
pokalaemia and inlammatory bowel conditions, and (iv) dependence (5, 12–14).
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Motives for misuse of opioid pharmaceuticals such as codeine range from self-treat-
ment for pain (physical and emotional) consistent with the drug’s main indication to that 
of recreational use for intoxicating purposes (15–17), with greater prevalence of recreation-
al use among men (18). Misuse and inappropriate use for management of sleep, stress and 
anxiety problems, its pleasurable efects, ease of access and some personality types (for 
example, addictive personality) are reported in the literature (5, 14, 17, 18). Codeine misuse 
and diversion also occur within problematic drug using networks (15, 16). 
Codeine dependence
Individuals dependent on codeine oten commence use in an efort to manage pain 
(12, 19), while others describe use of codeine containing medicines for ‘chemical coping’ in 
the case of its use for stress (14, 16). Codeine dependents are more likely to report chronic 
pain and use codeine for its intoxicating efects (11, 14). Moreover, many individuals de-
pendent on codeine do not view their use as problematic or see themselves as drug addicts 
needing help (11, 16, 19). Hidden populations of codeine misusers include those with ‘iat-
rogenic’ dependence following medical use of codeine for pain, anxiety or insomnia, rec-
reational drug users and problematic opiate dependents (5, 14, 19). Being able to acquire 
codeine containing products with no great di culty for therapeutic purposes lessens the 
patient’s ability to recognise that their use may be problematic, recognise withdrawals or 
that they are dependent (16, 20). Gaps in knowledge currently centre on identiication of 
risk proiles of codeine misusers and dependents, understanding of therapeutic and non-
therapeutic pathways and trajectories to misuse and dependence, as well as consumer 
displacement between prescriber, pharmacy supply and illicit sourcing via diversion or 
web retail (5, 7, 16)
Clinical proiles of patients dependent on codeine vary but are overrepresented by 
females, those in middle to late age, polysubstance users, alcohol users and those with 
underlying psychiatric conditions (5, 11, 13, 15, 16, 19). There is a need for the use of stan-
dardised criteria to determine client codeine dependence, with limited evidence available 
to guide the development of speciic treatment and referral pathways for codeine depen-
dence (6, 19–22). Furthermore, there is varying uptake of treatment interventions by indi-
viduals experiencing problematic use of codeine containing medicines due to issues relat-
ing to treatment stigma and poor consideration of needs (15, 16, 19, 20).
Managing codeine related issues
There is a need for ‘increased pharmaco-vigilance’ around codeine prescribing and 
over the counter dispensing. For example, advising patients and customers about the ben-
eits and risks of codeine containing medications, drug monitoring and screening in rela-
tion to codeine use within primary care and community pharmacies is required (5, 14, 
19–22). Current pharmacy strategies include removal of codeine containing products dis-
played at the point of sale, refusal or restriction of quantity sold to customers suspected of 
misusing, information provision by counter staf, on-site recording of suspected misuse 
and pharmacist interventions through supplementary questioning and referral to other 
health care professionals (14, 23). Strategies to empower pharmacy staf as custodians of 
medicine is warranted alongside patient information and brief interventions to raise pub-
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lic awareness and support individuals experiencing tolerance and withdrawal (5, 16, 21). 
For example, innovative developments based on national integrated prescriber and phar-
macy monitoring of medicines using real time reporting (RTR) analysis have emerged in 
the US, Canada, South Africa and Australia (24). Regulatory tactics to date have largely 
focused on guidelines for restricted supply (22, 23) and have met with some resistance 
from the pharmaceutical industry (25, 26).  
Codeine use, misuse and dependence are a public health concern and litle is known 
about such issues within medical, pharmacy and addiction treatment practice. CODEMIS-
USED is a Marie Curie FP7 EU funded project exploring codeine use, misuse and depen-
dence and involves both academic and industry partners from three countries – Ireland, 
the UK and South Africa (3). The project aims to establish what is known in relation to 
codeine use, misuse and dependence and address information gaps with regard to prac-
tice, policy and research. As part of this project, a scoping review (4) of the literature was 
carried out to explore and provide an overview of the type, extent and quantity of research 
on codeine use, misuse and dependence. The objective of this paper, therefore, is to present 
the indings arising from this scoping review, with a particular focus on practice. A num-
ber of implications and recommendations for policy and practice are identiied. 
DATA SOURCES
The scoping review that informs this paper was guided by Arksey & O’Malley’s 
framework (1). The following databases were searched: PubMed, EBSCO Host, Science 
Direct, EMBASE, PsycINFO, Cochrane library and Medline from 1994 to 2014. Search terms 
used were: ‘codeine; dihydrocodeine; opiate medication; opioid misuse/abuse/diversion/
addiction; opioid dependence; over the counter codeine/medicine; analgesics; prescription 
opioids; self-medication; pain; pharmacy; medical; treatment’. Follow-up search strategies 
involved hand searching, searching of pharmaceutical, health, medical and drug related 
websites, and contacting the following organisations: the World Health Organisation 
(WHO), International Narcotics Board (INCB), European Medicines Agency (EMA), Euro-
pean Monitoring Centre for Drugs and Drug Abuse (EMCDDA), authorised medicine 
boards in each of the European member states, Food and Drug Administration (FDA) USA, 
the Canadian pharmacy authority and the National Health Service (NHS) in the UK. 
A spreadsheet was created to chart relevant data (author, seting, study aim, design/
intervention, sample size, and results/outcomes) and to identify themes, sub-themes and 
gaps in the literature. Two reviewers independently screened titles and abstracts to deter-
mine inclusion status. A second screen of the full-text article by two other independent 
reviewers ensured that the studies were relevant to the aim and objectives of the review. 
A charting exercise identiied the speciic areas of the review, to which they could contrib-
ute, and data were extracted manually into a database. Disagreements of the relevance of 
data were resolved through discussion. 
A hand search of reference lists from published peer reviewed studies was also un-
dertaken. Articles beyond the search years were reviewed to establish relevance. Inclusion 
and exclusion criteria were set to determine the signiicance of the literature with regard 
to the aim and objectives of the review (Table I).
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Table I. Inclusion and exclusion criteria 
  Inclusion criteria
•  Research studies of prevalence or incidence of prescribed and over the counter codeine use, 
misuse, abuse, diversion, treatment and dependence in adult populations.
•  Research studies that describe the tampering of codeine containing medicines.
•  Reports of interventions for the treatment of codeine dependence. 
•  Reports of pharmacy based interventions for codeine use and misuse.
•  Research studies of at risk groups and other illicit drug users that use, misuse or are 
dependent on codeine. 
•  Research studies which  examine the efectiveness of codeine in pain management. 
•  Research studies examining pharmacovigilance, pharmacodynamics and pharmacokinetics 
with particular reference to codeine.
•  Literature in relation to the sale, consumption and manufacture of codeine.
•  Policy documents on the scheduling of codeine based products.
•  Policy documents and guidelines with particular reference to codeine.
  Exclusion criteria 
•  Anecdotal and opinion based literature about prescribed and over the counter codeine use, 
misuse, abuse, diversion, treatment and dependence in adult populations.
•  Literature not available in English.
•  Articles where full text was not available. 
•  Empirical studies examining codeine in animal populations.
Two researchers screened literature titles and abstracts to determine their inclusion 
status. Full text articles were reviewed and screened by two independent researchers to 
ensure they met the inclusion criteria. Full text articles were placed in a shared ile by the 
author, year and title of study to avoid duplication. References were managed by the cita-
tion manager Endnote®. This sotware facilitated the recording and organisation of all 
relevant literature. This allowed cross-checking of data records, removal of duplicates and 
extraction of information from the papers included in the review. 
Initial screening identiied a total of 3,105 articles, of which 475 met the inclusion cri-
teria. They were manually uploaded onto the shared folder and the Endnote database. 
Eight broad categories were identiied to assist in the organisation of the literature and 
data extraction (Table II).
The following information was extracted for each paper included in the review and 
tabulated: author, year, country of origin, study aims, methodology, sample size and set-
ting, outcome measures, results, authors’ conclusions and speciicity to codeine. Data were 
extracted for each paper by a single researcher and checked by a second researcher to en-
sure that it was accurate and comprehensive.  A qualitative synthesis of the literature was 
carried out within categories and sub-categories (Fig. 1). 
Review outcomes were further validated with a key stakeholder consultation exercise 
by virtue of the CODEMISUSED Expert Panel representing medicine control, pharmacy 
regulator, addiction and pharmacovigilant sectors.
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Fig. 1. Flow diagram for inclusion and exclusion of the literature. 
Table II. Broad categories used to organise the literature
Categories relating to codeine 
Production, manufacture, consumption and regulation of codeine.
Characteristics and proiles of codeine users.
Therapeutic use of codeine within healthcare.
Prevalence of codeine use, overuse, misuse and dependence.
Prevention of codeine overuse, misuse and dependence.
Consequences of codeine use/misuse(health and society).
Over the counter and internet sale of codeine medication.
Interventions and treatment for codeine misuse.  
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RESEARCH OUTCOMES
A number of implications and recommendations for practice were identiied and are 
presented under the following four main headings: (i) raising awareness, (ii) detecting and 
managing risk, (iii) dispensing practices, and (iv) monitoring and surveillance (4). These 
four headings were informed by the broad categories used in the scoping review to orga-
nise the literature (see Tables II and III).
Raising awareness
This theme illustrates the need to raise public and professional awareness of the safe 
use of medicines containing codeine, particularly in terms of compliant and appropriate 
use, recognising patient aberrance, the risks of dependence and associated health conse-
quences of excessive and/or long term use. A signiicant number of patients who consume 
medications cannot identify active ingredients in their chosen medications (28). A minor-
ity of customers appear willing to accept risks associated with increased access to over the 
counter medications containing codeine and other active ingredients (29). This is despite 
high public awareness of the abuse potential of OTC medicines (25) and pharmacists’ 
concerns about the safety and codeine misuse and dependence (5, 7, 19, 20). Pharmacists 
are trusted by the public as a source of information about over the counter medications (29, 
30). Dobbin and Tobin (20) have described particular characteristics of individuals misus-
ing codeine-containing pharmaceuticals, whereby they may not be identiied as addicts, 
the medication prescribed infers safety and sanctioning by the prescriber, and the prod-
ucts purchased have diferent legal consequences in comparison with illicit drug users. It 
is important to recognise variance in groups of codeine misusers, for example, parental 
medication of children, recreational users, university students, pharmacy customers, el-
derly, women, psychiatric patients, injecting drug users, non-treatment seeking individu-
als and drug treatment patients and target patient and customer awareness initiatives 
appropriately (5, 7, 19, 20). To challenge misinformed perceptions that codeine based prod-
ucts are low risk, more education for users of codeine containing medicines, targeted at 
codeine misusers, is needed about the risks associated with poly use of medication and 
intake of alcohol and illicit drugs (5) (see Table III).
Detecting and managing risk
This theme presents recommendations relating to harm reduction, public, patient and 
customer monitoring around inappropriate use of codeine containing medicines, misuse 
and aberrance, and pharmaceutical risk management. Evidence of the extent of use, non-
compliant use and misuse of pharmaceuticals containing codeine is limited (5, 7, 14, 19, 20, 
30). For example, in their review of the misuse of medicines across the European Union, 
Casati et al. (7) suggest that literature speciically targeting codeine misuse is limited be-
yond countries such as Norway and France but assume that misuse is widespread. The 
need to identify and carry out routine enquiries for all consumers, and particularly in rela-
tion to maternal medication use and suspected substance misuse, and psychiatric disor-
ders and their use of codeine-containing preparations, is recommended. Furthermore, 
clearer guidelines for the interpretation of DSM V criteria for abuse and dependence in 
chronic pain patients are needed.
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Table III. Practice implications and recommendations for managing codeine misuse and dependence
Raising awareness Detecting and managing risk Dispensing practices
Monitoring and surveillance of 
codeine
Use and misuse:
•  Develop and disseminate key health re-
lated messages about the risks of exceed-
ing therapeutic dosages of codeine based 
products. 
•  Heighten public awareness about the risks 
surrounding the use of codeine based 
products whilst driving. 
•  Further development of brief interven-
tions at point of sale to raise customer 
awareness of potential risk of tolerance 
and dependence over time.  
•  Further development of parenting classes 
to highlight the potential side efects of 
codeine such as respiratory depression 
when prescribed for children. Evidence 
suggests that codeine should not be used 
for children with neuromuscular disor-
ders, severe cardiac or respiratory condi-
tions, upper respiratory or lung infections, 
multiple trauma or extensive surgical pro-
cedures and is contraindicated in breast-
feeding women. Moreover, calculations of 
dose should be based on ideal body weight 
and not actual body weight.
 
Dependence:
Professional education and public awareness 
campaigns should seek to:  
•  Promote recognition and early detection 
by healthcare professionals of signs of de-
pendence and withdrawal in relation to 
codeine based products.
Use and misuse:
•  Incorporate routine enquiries about 
maternal medication use, including 
codeine-containing cough prepara-
tions, when evaluating new-born 
infants with evidence of cerebral in-
farction into assessment protocols.
•  Identify patients who are in need of 
psychological services to assist them 
in pain management.
•  Develop clearer guidelines for inter-
pretation of DSM V criteria for abuse 
and dependence in chronic pain pa-
tients, especially in cases of ‘mal-
adaptive or aberrant behaviour’.
•  In cases where substance misuse 
psychiatric disorders are suspected, 
a high index of suspicion for cough 
mixtures misuse/abuse is warranted. 
 
Dependence:
•  Assess opioid addiction with the mis-
use of ibuprofen-codeine combina-
tions when assessing patients with 
severe hypokalaemia, pancreatitis 
and medication overuse headache.
 
Managing codeine related issues:
•  Develop community pharmacy prac-
tice strategies that promote safety 
and include removal of potential 
products of abuse from  the point of 
sale or sight. 
Use and misuse:
•  Adopt a ‘universal precau-
tions’ systematic approach 
to each codeine sale, rather 
than a selective approach 
based on customer appear-
ance.
•  Provide clearer product la-
belling of the active ingre-
dients in over the counter 
and prescribed products. 
•  Remove potential products 
of abuse from sight in com-
munity pharmacies.
 
Dependence:
•  Refuse sales of codeine to 
users who are problematic 
misusers or dependent.
 
Managing codeine related issues:
•  Continue to expand the 
clinical and public health 
role of the community 
pharmacist with on-going 
inter-disciplinary training 
for counter assistants, phar-
macists and other health 
professionals. 
•  Introduce short term re-
stricted dispensing practices 
of codeine based products.
Use and misuse:
•  Develop prescription drug moni-
toring and national online pre-
scription systems.
•  Develop and evaluate real time in-
tegrated monitoring of the dis-
pensing of prescribed and over the 
counter use of codeine based prod-
ucts in community pharmacies. 
•  Ensure routine enquiries by health 
professionals of patients with re-
gard to prescribed and over the 
counter codeine medication use.
 
Dependence
•  Identify treatment seeking barri-
ers and experiences of people with 
codeine dependence.
 
Managing codeine related issues:
•  Monitor the use of prescription 
opioids in vulnerable groups (pa-
tients with chronic non-malignant 
pain, patients with cancer pain 
and illicit drug users)  to identify if 
opioids are substituting for or 
complicating mental health and 
addiction treatment outcomes, 
thereby minimising risk of over-
dose.
•  Share information in relation to 
codeine sales and consumers with 
other pharmacists.  
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Raising awareness Detecting and managing risk Dispensing practices
Monitoring and surveillance of 
codeine
•  Promote drug monitoring systems drug 
workers and clinicians should be aware of 
potential emerging harmful forms of 
home produced drug abuse, particularly 
in the case of injecting drug use.
 
Managing codeine related issues:
•  Promote improved awareness by profes-
sionals in relation to co-prescribing and 
efects on health.
•  Increase awareness and access to psycho-
logical treatments, for example, cognitive-
behavioural therapy, biofeedback and re-
laxation techniques for the treatment of 
chronic headache. 
•  Stronger awareness of and connections 
between the macro, meso and micro levels 
for policy development and analysis with 
regard to codeine use, misuse and depen-
dence is required.
•  Policy development to manage variability 
in OTC sales of codeine medicines across 
countries.
•  Policy development to guide development 
and implementation of identiied strate-
gies across countries.
•  Develop and improve referral mech-
anisms to primary care teams for 
people suspected to be misusing co-
deine or to be dependent. 
•  Develop strategies to detect decep-
tion, especially in pain related cases, 
thereby minimising risk of failing to 
improve or overdose.
•  Increase availability of disposable 
containers for unused prescriptions.
•  Develop strategies to manage access 
and reduce treatment barriers in re-
lation to codeine misuse and depen-
dence. For example, the reluctance of 
problem opiate users to access treat-
ment is an immediate concern. 
•  Develop appropriate harm reduction 
tactics (needle exchange, bleach dis-
tribution, hygiene, provision of il-
ters, foil packs to encourage route 
reversals, and safer injection facili-
ties), screening, treatment (opiate 
substitution therapy, antiretroviral 
therapy), therapy and prevention 
programmes that target injecting 
drug users who inject home drug so-
lutions made from codeine.
•  Develop in house pharma-
cy based brief interven-
tions at the point of sale 
along with supported de-
toxiication in pharmacies.
•  Provide needle and syringe 
exchange services target-
ing opiate injecting. Mar-
keting and promotion of 
more efective non-opioid 
combinations of simple an-
algesics.
•  Develop and evaluate ‘early warn-
ing systems’ in relation to codeine 
use, misuse and dependence. 
•  Consider further development and 
roll-out to other countries of initia-
tives that are similar to the South 
African Codeine Care Project, us-
ing The TrustaTAG™.
•  Monitor and manage conlicts be-
tween commercial and customer 
interests and between pharmacy, 
non-pharmacy and internet phar-
macy outlets.
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The development of community pharmacy strategies that promote safety and include 
the removal of potential codeine containing products of abuse from the point of sale or 
sight is recommended. Furthermore, improved referral mechanisms to primary care teams 
for people suspected of misusing codeine or being dependent is needed as well as the 
development of appropriate harm reduction tactics for injecting drug users who purchase 
codeine for home manufacture of deso-morphine (needle exchange, bleach distribution, 
hygiene, provision of ilters, foil packs to encourage route reversals, and safer injection 
facilities), along with screening, treatment and prevention programmes for all patients 
afected by codeine misuse and dependence. 
Dispensing practices
This theme illustrates details relating to pharmacy precaution, and protocols for sales 
and refusal to supply, training and support of staf, provision of needle and syringe pro-
grammes and manufacturer health warnings. Safety is central to pharmacists’ decision 
making with regard to medication dispensing (31). Pharmacy practice strategies that pro-
mote safety in relation to codeine dispensing practices are warranted (22, 31). For example, 
continual expansion of the clinical and public health role of the community pharmacist 
with on-going inter-disciplinary training for counter assistants, pharmacists and other 
health professionals is recommended. The use of a ‘universal precautions’ approach for all 
codeine sales rather than the current selective type methods based upon customer appear-
ance with further development of in house pharmacy based brief interventions at the point 
of sale, along with supported detoxiication in pharmacies warrants consideration, albeit 
given the challenges of the busy retail environment. Additionally, clearer product label-
ling of the active ingredients in OTC and prescribed codeine products with the removal of 
potential products of abuse from sight in community pharmacies is recommended, and 
with greater visibility of warnings on labels and lealets that clearly highlight ‘risk of ad-
diction’ or advise short term use of such medicines. Restrictions on pack sizes, advertising 
codes, prevention of public advertising, restrictions on product visibility and customer 
self-selection, pharmacy record keeping and direct involvement of pharmacists in sales are 
recommended (22, 23). Also, marketing and the promotion of more efective non-opioid 
combinations of simple analgesics could alleviate concerns of potential misuse and depen-
dence, and discourage potential pathways toward habit forming use in unsuspecting or 
ill-informed consumers.
Monitoring and surveillance of codeine
This theme presents recommendations relating to the monitoring and surveillance of 
codeine dispensing activity and estimations of the levels of customer use and misuse (both 
intentional and non-intentional) that remain problematic (5, 7, 14, 19, 20, 22, 31). For exam-
ple, the development of national online prescription systems with real time integrated 
monitoring of the dispensing of prescribed and OTC codeine based products in commu-
nity pharmacies is recommended. Furthermore, routine enquiries by health professionals 
of users with regard to prescribed and OTC codeine medication use must be promoted. In 
addition to therapeutic dependence and such forms of non-compliant use, the diversion, 
tampering, home manufacture and injecting of OTC and prescribed pharmaceuticals (con-
taining codeine and other opioids) is a pharmacy, drug surveillance and public health is-
sue  (5, 32). 
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There is a societal need for improved understanding of the risks of codeine use, mis-
use and dependence (5, 7, 14, 19–22). The potential risks relating to prescribed and OTC 
codeine use, misuse and dependence, and the impact that pharmacy controls and inter-
ventions may have is an area that requires further development (9, 20, 22, 29). A global 
emergence of ‘respectable addiction’ has occurred alongside a heightened awareness by 
the general public and health professionals with regard to this covert and hidden addic-
tion issue, and with a need for data monitoring of trends (22, 32). 
Relevance to existing literature and implications of results
Prescribed misuse, diversion, de-regulation and OTC availability of codeine com-
pounds open the potential for user adverse consequences and medical and pharmacy 
practice interventions (5, 7, 19–21). Health professionals need to be more aware of public 
lay drug deinitions around pharmaceutical opioid use, both prescribed and OTC, in 
order to avoid misunderstandings within their practice (5, 30). Equally, medical and 
pharmacy practitioner awareness relating to customer access to codeine based products, 
rising public displacement toward self-medication, and frequent interplay with pain 
conditions, coupled with the potential for unintentional misuse, health harms and over-
dose is warranted in order to maintain public surveillance and monitor those experienc-
ing misuse.
While appropriate directed use of codeine based products incurs litle risk, excessive 
or long term use of such products contributes to dependence, associated side efects and 
adverse and life threatening situations. The unpredictable nature of codeine’s pharmaco-
kinetics gives rise to concerns in relation to safety (3, 5). Continuous review and pharma-
covigilance of codeine based products is an essential activity that needs to be adhered to 
by both medical and pharmaceutical healthcare professionals (5). Recent developments 
include risk management and real-time monitoring of dispensing activity in order to pre-
vent patient opioid aberrant behaviour in the form of ‘double doctoring’ and ‘pharmacy 
hopping’ or consultation of multiple prescribers and pharmacy retailers (5, 24).
Prescribed opioid drug use is grounded in a mutual responsibility for transparent 
communication between patients and health or pharmacy professionals (6, 29, 31). Coor-
dinated responses in the form of patient or customer (in the case of OTC) education, 
screening for risk of abuse, patient agreements and screening are generally required to 
address drug compliance (15). Medical practitioners are advised to question those receiv-
ing opioid therapy about current, past and family histories with regard to misuse and 
addiction (5, 17), and their levels of over the counter and prescribed opioid use (7). Dis-
placement paterns have been observed between initial prescribed and OTC forms of 
misuse (16).
The management of codeine related issues requires a concerted efort by all stakehold-
ers given the link between the misuse of OTC codeine medicines and product availability 
(32, 33). Raising further lay and professional awareness with enhanced eforts to improve 
the knowledge, skills, conidence and commitment in relation to codeine use, misuse and 
dependence is required (19, 20, 32). Continued research, pharmacy practice innovation for 
risk management and drug surveillance, anti-tampering formulations, medical and phar-
macy practitioner education, and design of speciic pharmacy based screening and treat-
ment (both pharmacological and non-pharmacological) protocols is warranted. 
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CONCLUSIONS
This paper presents the indings arising from a scoping review of codeine use, misuse 
and dependence with a particular focus on implications and recommendations for prac-
tice. We found many relevant papers, highlighting a growing interest in issues relating to 
codeine use, misuse and dependence. While the correct medical use of codeine based 
products is comparatively safe, the unpredictable nature of codeine’s pharmacokinetics 
gives rise to concerns in relation to safety (3, 5). Recent initiatives relating to risk manage-
ment and real-time monitoring of dispensing activity in order to prevent patient opioid 
aberrant behaviour underpinned by public availability are welcome developments (5, 23). 
While many speciic topic areas are identiied, further research and analysis of these areas 
is required. 
While the scoping review followed a systematic process, it cannot claim to be exhaus-
tive in its coverage. In particular, there may be on-going, as yet unpublished pieces of re-
search not described here. It must also be acknowledged that while our search was com-
prehensive and included a wide body of literature, across varying populations, conditions 
and study designs, some literature may have been missed. Furthermore, social media are 
constantly evolving, leading to challenges in keeping the search updated.
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